Z-VDVAD-FMKCaspase-2 inhibitor CAS# N/A |
- Q-VD-OPh hydrate
Catalog No.:BCC1125
CAS No.:1135695-98-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-DEVD-FMK
Catalog No.:BCC1137
CAS No.:210344-95-9
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Inhibitor
Catalog No.:BCC1143
CAS No.:54135-60-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | N/A | SDF | Download SDF |
| PubChem ID | 25108684 | Appearance | Powder |
| Formula | C32H46N5O11F | M.Wt | 695.73 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Sequence | VDVAD (Modifications: Val-1 = Z-Val, Aps-2 = Asp(OMe), Asp-5 = (OMe)-fluoromethylketone) | ||
| Chemical Name | methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-2-[[(2S)-4-methoxy-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxopentanoate | ||
| SMILES | CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CC(=O)OC)NC(=O)C(C(C)C)NC(=O)OCC1=CC=CC=C1 | ||
| Standard InChIKey | ANTIWMNLIROOQF-IREHUOSBSA-N | ||
| Standard InChI | InChI=1S/C32H46FN5O11/c1-17(2)26(30(44)34-19(5)28(42)35-21(23(39)15-33)13-24(40)47-6)37-29(43)22(14-25(41)48-7)36-31(45)27(18(3)4)38-32(46)49-16-20-11-9-8-10-12-20/h8-12,17-19,21-22,26-27H,13-16H2,1-7H3,(H,34,44)(H,35,42)(H,36,45)(H,37,43)(H,38,46)/t19-,21-,22-,26-,27-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Z-VDVAD-FMK Dilution Calculator
Z-VDVAD-FMK Molarity Calculator
Abstract
The effect of Z-VDVAD-FMK, a caspase-2 inhibitor, on lipid profile was evaluated by NR staining.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.
When etoposide-induced activation of pro-caspase-2 is subverted by Z-VDVAD-FMK or stable transfection of pro-caspase-2 antisense, cytochrome c release and other manifestations of apoptosis are attenuated.
OxyHb significantly activated both caspase-2 and caspase-3 in bovine brain microvessel endothelial cells. The irreversible caspase inhibitors Z-VDVAD-FMK (caspse-2 inhibitor) and Z-DEVD-FMK (caspase-3 inhibitor) significantly reduced cell detachment, caspase-2 and -3 activities, DNA ladders, and proteolytic cleavage of PARP2. Activation of caspase-2 and caspase-3 is essential for OxyHb induced apoptosis in endothelial cells, and Z-VDVAD-FMK and Z-DEVD-FMK have the potential to protect cells.
The minimal-length inhibitor of caspase-2, Z-VDVAD-fmk, which also inhibits caspases 3 and 73, prevented doxorubicin-induced nuclear apoptosis, but not cell death4.
References:
1. J. D. Robertson, M. Enoksson et al. Caspase-2 Acts Upstream of Mitochondria to Promote Cytochrome c Release during Etoposide-induced Apoptosis. The Journal of Biological Chemistry. 277, :29803–29809, 2002
2. T. Meguro, B. Chen et al. Caspase Inhibitors Attenuate Oxyhemoglobin-Induced Apoptosis in Endothelial Cells, Stroke. 2001; 32:561-566.
3. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., Ghayur, T., Brady, K. D., and Wong, W. W. (1997). Substrate specificity of caspase family proteases. J. Biol. Chem. 272, 9677–9682.
4. Gamen et al (2000) Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Dym loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp.Cell Res. 258 223.
- Isoboonein
Catalog No.:BCN4545
CAS No.:99946-04-0
- Bullatantriol
Catalog No.:BCN4543
CAS No.:99933-32-1
- 3-(3,4-Dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide
Catalog No.:BCN8535
CAS No.:99933-30-9
- RGD (Arg-Gly-Asp) Peptides
Catalog No.:BCC5349
CAS No.:99896-85-2
- Isoboonein acetate
Catalog No.:BCN4542
CAS No.:99891-77-7
- Kaempferol 3-O-arabinoside
Catalog No.:BCN4541
CAS No.:99882-10-7
- Droxinostat
Catalog No.:BCC2157
CAS No.:99873-43-5
- Rotigotine
Catalog No.:BCC1907
CAS No.:99755-59-6
- Scholaricine
Catalog No.:BCN4539
CAS No.:99694-90-3
- 14-Benzoylneoline
Catalog No.:BCN6493
CAS No.:99633-05-3
- Ro 19-4603
Catalog No.:BCC7228
CAS No.:99632-94-7
- Uncinatone
Catalog No.:BCN4547
CAS No.:99624-92-7
- Acetyl Perisesaccharide C
Catalog No.:BCN8666
CAS No.:110764-09-5
- Dihydroartemisinic acid
Catalog No.:BCN8547
CAS No.:85031-59-0
- Rhein-8-glucoside
Catalog No.:BCN8548
CAS No.:34298-86-7
- Cistanoside F
Catalog No.:BCN8549
CAS No.:97411-47-7
- Vinaginsenoside R3
Catalog No.:BCN8550
CAS No.:156012-92-9
- 28-Demethyl-beta-amyrone
Catalog No.:BCN8551
CAS No.:73493-60-4
- Ilexsaponin B2
Catalog No.:BCN8552
CAS No.:108906-69-0
- Trans sodium crocetinate
Catalog No.:BCN8553
CAS No.:591230-99-8
- Panasenoside
Catalog No.:BCN8554
CAS No.:31512-06-8
- Ginsenoside Ra2
Catalog No.:BCN8555
CAS No.:83459-42-1
- Uvarigranol B
Catalog No.:BCN8556
CAS No.:164204-79-9
- Rupestonic acid
Catalog No.:BCN8557
CAS No.:115473-63-7
[Studies on the chemical constituents of Taxus yunnanensis].[Pubmed:1688071]
Yao Xue Xue Bao. 1991;26(10):747-54.
The ethanolic extract of the bark of Taxus yunnanensis Cheng et L. K. Fu. showed significant antineoplastic effect on the transplantable tumors in mice. The life survival of P388 leukemic bearing mice was increased (84%) and the growth of B16 melanoma in mice was inhibited (53%). From this extract eight taxane diterpenoids and taxane alkaloids have been isolated. Seven of them have been identified as taxinine E(1), taxinine J(2), 1-acetoxy-5-deacetyl baccatin I(4), baccatin III(5), taxol (6), cephalomannine (7), 7-xylosyl-10-deacetyl taxol (8) from their physical and spectroscopic properties. A new taxane diterpenoid, named yunnanxane (3) was elucidated as taxa-4 (20), 11-diene-2 alpha, 5 alpha, 10 beta, 14 beta-tetraoln2 alpha,5 alpha,10 beta-triacetaten-14 beta-alpha-methyl-beta- hydroxylbutyratebyhighfield 1H NMR, 13C NMR, 1H-1HCOSY, 13C-1HCOSY, 13C-1HCOLOC and X-ray analysis. It showed the inhibitory effect on A2780 DDP, KB and HCT-8 cell line in vitro. All of the eight compounds were isolated from this species for the first time.
